8^th International Conference on Central Nervous System Disorders and Therapeutics July 19-20, 2023 Rome, Italy

Session 1: Central Nervous System Disorders

Central nervous system diseases, also known as central nervous system disorders, are a group of neurological disorders that affect the structure or function of the brain or spinal cord, which collectively form the central nervous system (CNS)

• Brain Dysfunction
• Cerebellum: Aging and Cognitive Syndrome
• Pathophysiology of CNS Disorders
• White Matter Diseases
• Hydrocephalus
• Spinal Meningitis
• Neuromyelitis Optica
• Neuronal and Axonal Damages
• Encephalitis
• Case studies on Spinal Disorders
• Arnold–Chiari Malformation
• Functional and Structural Disorders
• Fibromyalgia Syndrome
• Cerebral Edema
• Brain Infections and Abscess
• Holoprosencephaly

Session 2: Cognitive Neuroscience

Cognitive neuroscience is the scientific field that is concerned with the study of the biological processes and aspects that underlie cognition, with a specific focus on the neural connections in the brain which are involved in mental processes. It addresses the questions of how cognitive activities are affected or controlled by neural circuits in the brain. Cognitive neuroscience is a branch of both neuroscience and psychology, overlapping with disciplines such as behavioural neuroscience, cognitive psychology, physiological psychology and affective neuroscience. Cognitive neuroscience relies upon theories in cognitive science coupled with evidence from neurobiology, and computational modelling.

• Neurocognitive
• Cognition Psychology
• Evolution and Social Cognition
• Cognitive Development
• Methods of cognitive Neuroscience
• Neurobehavioral and Cognitive Disorders
• Cognitive Genomics & Behavioural Genetics
• Cognitive Rehabilitation Therapy

Session 3: CNS and Neurosurgery

Most people think of neurosurgery as brain surgery — but it is much more!

It is the medical specialty concerned with the diagnosis and treatment of patients with injury to, or diseases/disorders of the brain, spinal cord and spinal column, and peripheral nerves within all parts of the body. The specialty of neurosurgical care includes both adult and paediatric patients. Dependent upon the nature of the injury or disease a neurological surgeon may provide surgical and/or non-surgical care.

• Post-Surgical Neuralgias
• Tumour and Metastatis
• Current Neurosurgery Methods
• Vascular Malfunctions and Surgery
• Anatomical and Functional Neural Circuits
• Neurosurgery Diagnostic Tests
• Neuropathology

Session 4: Cerebral Disorders

Your brain is your body’s control centre. It’s part of the nervous system, which also includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your senses to the muscles throughout your body. When your brain is damaged, it can affect many different things, including your memory, your sensation, and even your personality. Brain disorders include any conditions or disabilities that affect your brain. This includes conditions that are caused by:

• Illness
• Genetics
• Traumatic injury

These disorders include epilepsy, Alzheimer disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders, multiple sclerosis, Parkinson's disease, neuro infections, brain tumours, traumatic disorders of the nervous system due to head trauma

• Cerebral Hemorrhage
• Hypertension
• Cerebral Embolism
• Cerebral Aneurysm
• Stroke and Transient Ischaemic Attack
• Vascular Malformation
• Risk factors for Cerebrovascular Diseases
• Epidemiology of Cerebrovascular Diseases
• Technological Advances in Vascular Surgery

Session 5: Brain Tumour & Imaging

Diagnosing a brain tumour usually begins with magnetic resonance imaging (MRI). Once MRI shows that there is a tumour in the brain, the most common way to determine the type of brain tumour is to look at the results from a sample of tissue after a biopsy or surgery.

• Neurology of Brain
• Neuroimaging Software
• Neuroradiology
• Brain Imaging Techniques
• Structural & Functional Imaging
• Invasive and Non-Invasive Imaging of Tumour
• Radiation & Chemotherapy
• Pathophysiology of Brain Tumours
• Neurobiology of Tumours
• Novel Treatment Strategies

Session 6: Spinal Cord and Disorders

Spinal cord disorders can cause permanent severe problems, such as paralysis or impaired bladder and bowel control (urinary incontinence and fecal incontinence). Sometimes these problems can be avoided or minimized if evaluation and treatment are done quickly. Causes of spinal cord disorders include injuries, infections, a blocked blood supply, and compression by a fractured bone or a tumour. Typically, muscles are weak or paralyzed, sensation is abnormal or lost, and controlling bladder and bowel function may be difficult. Doctors base the diagnosis on symptoms and results of a physical examination and imaging tests, such as magnetic resonance imaging.

• Arachnoiditis
• Spinal Disorders Test
• Spine Tumours
• Transverse Myelitis
• Syringomyelia
• Spina Bifida
• Spinal stroke
• Scoliosis Spine
• Sciatica
• Spinal Stenosis
• Cauda Equina Syndrome
• Therapeutic Approaches for Spinal Disorders

Session 7: Neurodegenerative Disorders

Neurodegenerative disorders encompass a wide range of conditions that result from progressive damage to cells and nervous system connections that are essential for mobility, coordination, strength, sensation, and cognition. Neurodegenerative diseases affect millions of people worldwide. Although there isn’t a complete cure for most of these complex neurological diseases

• Alzheimer Disease
• Neuroinflammation Diseases
• Werdnig-Hoffmann Disease
• Prion disease
• Amyotrophic Lateral Sclerosis Disease
• Migraine and Headaches
• Autism
• Schizophrenia
• Frontotemporal Lobar Degeneration
• Multiple Sclerosis Disease
• Parkinsonism
• Huntington Disease

Session 8: Child Neurology

Child neurology, also known as paediatric neurology, specializes in the diagnosis and management of neurologic conditions during the neonatal period, infancy, early childhood, and adolescence. Child neurologists have special competence in the genetic and metabolic problems, malformations, and developmental problems of childhood, including epilepsy, cerebral palsy, muscular dystrophy, mental retardation, autism, Tourette's syndrome, Batten's disease, neurofibromatosis, learning disabilities, complex metabolic disorders, and a host of nerve and muscle diseases. Child neurologists act as consultants to primary care physicians as well as provide continuing care for chronic neurological conditions. Like other paediatric specialties, it is a specialty that requires the ability to work with patients who may have limited or non- existent verbal skills.

• Congenital Hydrocephalus
• Clinical Trials for Paediatric Epilepsy
• Paediatric Neurology Practice
• Paediatric Vestibular Disorders
• Paediatrics Tumours
• Attention Deficit Hyperactivity Disorder (ADHD)
• Neural Rube Defects
• Hereditary Ataxy
• Neonatal Encephalopathy
• Advance treatment of Paediatric Neurological Disorders

Session 9: Neuroimmunology

Neuroimmunology is a field combining neuroscience, the study of the nervous system, and immunology, the study of the immune system. Neuroimmunologists seek to better understand the interactions of these two complex systems during development, homeostasis, and response to injuries.

• Epigenetics of Neuroimmunology
• Paediatric Neuro-immunology
• Neuroimmuno Genetics
• Neurodevelopmental Diseases and Thermogenesis
• Autoimmune Neuropathies
• Antibody-mediated Disorders
• Neuroimmunology Test
• Psychoneuroimmunology
• Neuromics, Neuroproteomics, Neurogenomics and Human Brain Proteome

Session 10: Neuropharmacology

Neuropharmacology is a branch of study which deals with drugs that affect the nervous system. It is focused on the development of compounds that may be of benefit to individuals who suffer from neurological or psychiatric illness. Neuropharmacology itself came into existence only five decades ago, prior to which there were only four drugs available for nerve disorders: morphine, caffeine, nitrous oxide, and aspirin. In the next 50 years, a new set of drugs such as antihistamines, barbiturates, and opioid analogs have emerged.

• Molecular and Behavioural Neuropharmacology
• Neuroethics
• Available Therapeutics
• Neural Circuits Regulating Appetite
• Clinical Pharmacists
• Surgical Aggression and Anesthesia
• Physical Therapy
• Antipsychotic drugs/ Neuroleptics
• Clinical Neuropharmacology
• Future Aspects of Neuropharmacology

Session 11: Neurochemical Transmission

Regardless of the type of neuron under consideration, the fundamental steps in chemical transmission are the same. Each of these steps is a potential site for pharmacological intervention in the normal transmission process:

1. Synthesis of the transmitter

2. Storage of the transmitter

3. Release of the transmitter by a nerve action potential

4. Interaction of the released transmitter with receptors on the effector cell membrane and the associated change in the effector cell

5. Rapid removal of the transmitter from the vicinity of the receptors

6. Recovery of the effector cell to the state that preceded transmitter action

• Dopamine
• Interneurons: Coordinators of Neuronal Synchrony
• Advances in Astrocyte-Neuron Interactions in Health and Disease
• Neurotransmission Receptors
• Chemical Neurotransmitters
• Human Synapses
• Monoamines
• Neuropeptides
• Serotonin
• Drug interaction in Various Stages in Neurotransmitters

Session 12: Novel Drug Development & its Effects

The Novel Drug Discovery Program focuses on activity guided isolation and structure elucidation of bioactive compounds from natural sources with high throughput screening. The program includes synthesis of bioactive compounds, analogues and internal standards for further drug development and bioavailability studies. Novel therapies are therapies entirely new to veterinary medicine either because they are genuinely novel and have not been previously used in the context of a medicine, or new only to the veterinary domain, although well known in terms of research, and possibly in the context of human medicine.

• Anti-Neurodegenerative Drug Discovery
• Nanoparticles as Drug Carriers
• Role of Drug Metabolism in Drug Development
• Enzyme Kinetics
• Metabolism Mediated Drug-Drug Interactions
• Blood Brain Barrier (BBB)
• Centrally Acting Analgesics
• Neurotransmitters, Neuromodulators, and Neuroreceptors
• Neural Stem Cells and Gene or Cell Therapy
• Ion Channels, Transporters and Neurotransmitter Receptors
• Neurological Drug Targets

Session 13: Computational Neurosciences

Computational neuroscience (also known as theoretical neuroscience or mathematical neuroscience) is a branch of neuroscience which employs mathematical models, theoretical analysis and abstractions of the brain to understand the principles that govern the development, structure, physiology and cognitive abilities of the nervous system. Computational neuroscience involves studying brain function through computer modeling and mathematical analysis. Computational neuroscientists perform research in which they collect data and create computer models based on the electrical patterns and biological functions of the brain.

• Neuroinformatics
• Neural Science and Behaviour
• Computational Drug Response Models
• Neural Network Theory & Models
• Neural Network Applications
• Neuro Engineering

Session 14: Case Study on CNS

The CNS consists of the brain and spinal cord. The brain is protected by the skull (the cranial cavity) and the spinal cord travels from the back of the brain, down the centre of the spine, stopping in the lumbar region of the lower back. The brain and spinal cord are both housed within a protective triple-layered membrane called the meninges. The central nervous system has been thoroughly studied by anatomists and physiologists, but it still holds many secrets; it controls our thoughts, movements, emotions, and desires. It also controls our breathing, heart rate, the release of some hormones, body temperature, and much more. The retina, optic nerve, olfactory nerves, and olfactory epithelium are sometimes considered to be part of the CNS alongside the brain and spinal cord. This is because they connect directly with brain tissue without intermediate nerve fibres.

• Case Studies Related to CNS Disorders
• Case Studies on Child Neurology
• Case Studies on Neuroimmunology
• Case Studies on Neuro-Oncology
• Case Reports on Brain Tumour
• Case Studies on Cerebrovascular Disorders
• Case Reports Related to Neuroimmunology Diseases

Session 15: Clinical Trials on CNS

CNS clinical trials bring specific challenges, including managing placebo response, incorporating soft endpoints, and require a particular focus on reducing patient burden. Unsurprisingly this had led to a challenging of accepted and established norms by CNS drug developers.

• Alzheimer’s Disease and Cognition Clinical Trial
• Neurology Clinical Trial
• Pain Management and Analgesia Clinical Trial
• Psychiatry Clinical Trial

Session 16: CNS Biomarkers

Biomarkers provide detailed measures of abnormal changes in the brain, which can aid in early detection of possible disease in people with very mild or unusual symptoms. People with Alzheimer's disease and related dementias progress at different rates, and biomarkers may help predict and monitor their progression.

• Neuroimaging Enrichment for CNS Disease
• CNS Drug Development Using Biomarkers
• Cerebro Spinal Fluid Biomarkers
• Biomarker Challenges in Rare Diseases

Session 17: Neurological Nursing

Neuroscience nurses care for people with a variety of neurological conditions and disorders across the lifespan and in all health care settings. There are many specialities encompassed within this field of practice. Most people with long-term neurological conditions live active and fulfilling lives and are cared for out of hospital, but may require admission to hospital for reasons that may or may not be related to their disorder. Many people will be supported by a specialist nurse and nursing team during their hospital stay.

• Advance Practice Nursing
• Acute Ischemic Stroke Patients
• Paediatrics Nursing
• Neuroscience Nursing
• Trauma & Critical Care Nursing

Session 18: MOG antibody disease (MOGAD)

MOG antibody disease (MOGAD) is a recently coined neuro-inflammatory condition that preferentially causes inflammation in the optic nerve but can also cause inflammation in the spinal cord and brain. Myelin oligodendrocyte glycoprotein (MOG) is a protein that is located on the surface of myelin sheaths in the central nervous system. While the function of this glycoprotein is not exactly known, MOG is a target of the immune system in this disease. The diagnosis is confirmed when MOG antibodies in the blood are found in patients who have repeated inflammatory attacks of the central nervous system.

• Neuromyelitis Optica Spectrum Disorder (NMOSD)
• Transverse Myelitis (TM)
• Acute Disseminated Encephalomyelitis (ADEM)
• Optic Neuritis (ON)

Session 19: Neuro-Oncology

Neuro-oncology is a unique, developing neurologic subspecialty that combines many aspects of neurology with those of cancer biology. The neuro-oncologist is expert in both the diagnosis and management of primary brain tumors and neurologic complications of cancer. A career in neuro-oncology presents opportunities to utilize a multidisciplinary team approach and the application of cutting-edge technology toward patient treatment while providing compassionate patient care. Neuro-oncology can trace its modern origins to the 1970s, when the first therapeutic trials were begun. The treatment and management of primary brain Tumors is now a rapidly evolving field.

• Tumors
• Malignant brain cancers

The global central nervous system therapeutic market size was valued at 116.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. Advancements in diagnostics and therapeutics of central nervous system (CNS) diseases are expected to increase the treatment rate globally. Moreover, the increasing prevalence of central nervous system disorders and the rising demand for effective therapeutics options are expected to boost market growth over the forecast years. According to a report published by the WHO, central nervous system disorders such as Alzheimer’s disease, multiple sclerosis, epilepsy, Parkinson’s disease, and stroke affect more than 1 billion people worldwide. The high unmet medical need has led all the major pharmaceutical companies to invest and develop novel therapies for the treatment of CNS diseases.

Rising approval of generic products owing to patent expiration of key products, such as Copaxone and Invega, has led to an increase in treatment rate, especially in low- and middle-income countries. For instance, in 2018, the FDA approved two new generic forms of Copaxone, which is further expected to increase competitive rivalry in the market for central nervous system therapeutic. Regulatory guidelines and critical clinical trials are encouraging the entry of new products into the market for central nervous system therapeutic. These drugs are monitored for their efficacy, dosage, formulation, and aftereffects. For instance, the U.S. FDA has designated CNS Pharmaceuticals’ berubicin as an orphan drug for the treatment of patients with malignant gliomas.

The CNS therapeutics market has experienced extensive R&D efforts in the past decade, which have resulted in the introduction of novel drug-delivery systems. The advancements in the drug-delivery systems are expected to increase the adoption of a novel therapy to treat central nervous system diseases. These novel drug-delivery systems have an edge over conventional methods owing to reduced adverse effects. The demand for a novel drug-delivery system is owing to ease of delivery and availability of different dosage forms. For instance, the introduction of transdermal patches for central nervous system disorders provides an accurate amount of medicine and relief mostly for around 24 hours.

The presence of strong pipeline products is expected to propel the market for central nervous system therapeutics over the forecast period. The key pharmaceutical players are focusing on new therapies to prevent or improve the symptoms of neurological disorders. Companies such as Biogen, AbbVie Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, and others have their drug candidates in the last phases of the development and are expected to be commercialized in the foreseeable future. The launch of these novel drugs is anticipated to boost the market for central nervous system therapeutic. Most of the drugs in the development aim to interrupt the disease process by impacting the brain changes associated with diseases.

The increasing awareness regarding mental health and neurodegenerative diseases by government and non-government organizations is anticipated to increase the treatment rate globally. Organizations such as WHO and others conduct various awareness programs to increase awareness among people living with central nervous system disorders. Furthermore, the Spanish government has launched a national plan to tackle dementia that includes key targets for improving dementia awareness, patient-centric health and social care, and promotion of research and innovation. The focus on neurodegenerative disease research is higher in Spain.

Disease Insights

The neurodegenerative disease segment dominated the market for central nervous system therapeutic and accounted for the largest revenue share of 39.4% in 2020. The segment is expected to continue its dominance over the forecast period. The high prevalence of neurodegenerative diseases such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease and the high cost of neurodegenerative diseases is anticipated to increase the segment share from the year 2020 to 2028. Moreover, strong pipeline products for the treatment of neurodegenerative disease are expected to drive the segment. For instance, there are more than 130 drug candidates in the pipeline globally for the treatment of Alzheimer’s disease.

Mental health was estimated to be the second-largest segment in the central nervous system therapeutic market. High patient base of anxiety disorder and epilepsy are the major growth contributors. Moreover, the presence of strong pipeline drugs for the treatment of psychotic disorders is anticipated to drive the market for central nervous system therapeutic at a lucrative rate over the forecast period.

CNS cancer is expected to be the fastest-growing segment over the forecast period and is projected to exhibit a CAGR of 10.1%. Its high growth rate can be attributed to increasing prevalence and mortality and growing demand for treatment. For instance, around 70,800 people in the United States are diagnosed with brain cancer every year, which represents 1.4% of the total cancer incidence and causes about 2.4% of all cancer deaths in the U.S. GBM is the most common brain cancer and accounts for more than half of all brain cancers. In 2018, around 300,000 people were diagnosed with brain cancer worldwide and caused deaths of nearly 240,000 in the same year. Also, constant R&D efforts by pharmaceutical companies, coupled with increasing investment by government and private entities, are expected to support the adoption of CNS drugs in cancer treatment.

The neurodegenerative diseases and mental health segments collectively held more than 75.0% share of the market. High prevalence and technological collaborations are factors that can be attributed to the largest share of these segments and will continue to show its dominance over the forecast period. For instance, in January 2021, Atalanta Therapeutics has collaborated with Biogen and Genentech for the development of RNAi therapeutics for the treatment of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease.

Regional Insights

North America dominated the market for central nervous system therapeutic and held the largest revenue share of 47.3% in 2020. The presence of strong players in the region and rising initiative undertaken by key players to develop novel therapies for different central nervous system disorders are factors expected to increase the overall market share. Moreover, the constantly rising incidence of mental health and neurodegenerative disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s disease, and epilepsy is fueling the demand for central nervous system therapeutics in the North America region. Awareness campaigns about diagnosis and treatment of CNS diseases run by pharmaceutical companies and better reimbursement policies for the CNS diseases treatment increase the treatment rate in the region.

In Asia Pacific, the market for central nervous system therapeutic is expected to grow at the highest rate over the next eight years. Improving healthcare infrastructure in emerging markets such as India and China and a large patient base with high unmet medical needs are some factors expected to drive treatment adoption rate during the forecast period. Moreover, increasing awareness regarding mental health and initiatives of the government and non-profit organizations are increasing market growth. In countries like China and India, many non-profit organizations offer treatment for patients living with central nervous system disorders.

Key Companies & Market Share Insights

Large pharmaceutical companies are highly investing in the development of novel therapies to treat central nervous system diseases. In February 2020, Biogen announced USD 2.72 billion deal with Sangamo Therapeutics to develop gene regulation therapies to treat Alzheimer’s disease. Some of the prominent players in the central nervous system therapeutic market include:

• Biogen
• Otsuka Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Merck & Co.
• Astra Zeneca
• Shire PLC
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Pfizer, Inc

Central Nervous System Therapeutic Market Report Scope

The 8th International Conference on Central Nervous System Disorders and Therapeutics will exhibit the products and services from commercial and non-commercial organizations like Drug manufactures, Clinical Trial Sites, Management Consultants, Chemists, Pharmacists, Business delegates and Equipment Manufacturers.

Why to attend CNS Disorders 2023?

• Best platform to develop new partnership & collaborations.
• Best location to speed up your route into every territory in the World.
• 89% our conference attendees are the Key contact in their labs purchasing decisions.
• Our exhibitor booths were visited 4-5 times by 80% of the attendees during the conference.
• Past exhibitor’s feedback reveals ample of enquiries perceived from the conference attendees.
• Network development with both Academia and Business.

• Exhibitor benefits:

  • One exhibit booth (Size-3X3 sqm).
  • 1 page publication of the exhibitor profile in the souvenir- CNS Disorders 2023.
  • Promotion through the conference website.
  • Promotional video on company products during the conference (Post session and Breaks).
  • One complimentary scientific program registration.
  • Logo recognition in the Scientific program, Conference banner and flyer.
  • One A4 flyer insert in the conference kit.
  • An opportunity to sponsor 1 Poster Presentation Award.
  • Post conference -submission of the mailing list.